Vertex and entrada therapeutics establish collaboration to discover and develop endosomal escape vehicle (eev) therapeutics for myotonic dystrophy type 1 (dm1)

Boston--( business wire )--vertex pharmaceuticals incorporated (nasdaq: vrtx) and entrada therapeutics, inc. (nasdaq: trda) today announced a global collaboration focused on discovering and developing intracellular endosomal escape vehicle (eev™) therapeutics for myotonic dystrophy type 1 (dm1). the collaboration includes entrada's program for dm1, entr-701, which is in late-stage preclinical development.
VRTX Ratings Summary
VRTX Quant Ranking